Details of Drug-Drug Interaction
| Drug General Information (ID: DDI1378HGN) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Trimetrexate | Drug Info | Glucarpidase | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antifungal Agents | Antidotes | |||||||
| Structure | |||||||||
| Mechanism of Trimetrexate-Glucarpidase Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased metabolism (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Trimetrexate | Glucarpidase | |||||||
| Mechanism | Glucarpidase substrate | Glucarpidase recombinant enzyme | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacokinetics | ||||||||
| Factor Description | Alters the metabolism of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | On theoretical grounds, caution is advised if glucarpidase is administered in combination with potential substrates such as folate antimetabolites other than methotrexate. With leucovorin, experts recommend administering it two to four hours before or after a dose of glucarpidase. The same precaution may be appropriate with other potential substrates of glucarpidase, although clinical data are currently lacking. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||||||||||||||||
| 2 | Product Information. Voraxaze (glucarpidase). BTG International Inc, West Conshohocken, PA. | ||||||||||||||||||